A 5-Br-1-Propylisatin Derivative as a Promising BRD9 Ligand: Insights from Computational and STD NMR Investigation.

Erica Gazzillo, Gabriel Rocha, Maria Giovanna Chini, Gianluigi Lauro, Jesús Angulo, Giuseppe Bifulco

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Erica GazzilloDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.

Gabriel RochaInstitute for Chemical Research (IIQ), CSIC-University of Seville, 49 Américo Vespucio St, 41092 Seville, Spain.ORCID 0009-0004-5673-5943

Maria Giovanna ChiniDepartment of Biosciences and Territory, University of Molise, Contrada Fonte Lappone, 86090 Pesche, Italy.

Gianluigi LauroDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0000-0001-5065-9717

Jesús AnguloInstitute for Chemical Research (IIQ), CSIC-University of Seville, 49 Américo Vespucio St, 41092 Seville, Spain.ORCID 0000-0001-7250-5639

Giuseppe BifulcoDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.

Funding

AIRC MFAG 2017 - ID. 20160Ministero dell'università e della ricerca 2022RCTY7M

6 · The paper itself

Abstract

Bromodomain-containing protein 9 (BRD9) belongs to the non-canonical BAF chromatin remodeling complex and represents a relevant therapeutic target in pathologies featuring dysregulated epigenetic control. The absence of clinically validated inhibitors and the need for diversified chemical entities highlight the interest in identifying new scaffolds targeting this protein. In this study, Saturation Transfer Difference Nuclear Magnetic Resonance (STD NMR) was employed to assess its suitability for characterizing BRD9-ligand interactions within a fragment-based discovery framework. STD NMR conditions were first optimized using the known BRD9 ligand

Indexed as

IsatinTranscription FactorsBinding SitesBromodomain Containing ProteinsHumansLigandsMagnetic Resonance SpectroscopyModels, MolecularPharmacophoreProtein BindingBRD9 protein, humanBromodomain Containing ProteinsIsatinLigandsTranscription FactorsbromodomainepigeneticisatinSTD NMRvirtual screening

Identifiers

PMID41752361

DOI10.3390/molecules31040582

PMCPMC12942702

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.